Protocol Ledger

NCT06532006 · Phase III · RECRUITING

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Interventional Phase III clinical trial protocol NCT06532006 sponsored by Shanghai Henlius Biotech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-22 Enrollment: 550 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06532006
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)550 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06532006
Protocol FieldVerified Registry Value
NCT IdentifierNCT06532006
Consolidated Lead SponsorShanghai Henlius Biotech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment550 participants (ESTIMATED)
Registered Start Date2024-11-22
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI